No abstract

Tenatoprazole 40 mg daily provides a prolonged duration of acid suppression and a shorter nocturnal acid breakthrough in healthy volunteers, even after stopping the drug. Thus, tenatoprazole may provide greater clinical efficacy for patients in whom a once daily PPI is ineffective. Further studies are indicated.

SUMMARYBackground: Cyclo-oxygenase-2-selective non-steroidal anti-inflammatory drugs are intended to preserve cyclooxygenase-1-mediated gastroprotection and platelet function, whilst inhibiting cyclo-oxygenase-2-mediated inflammation. Aim: To assess the gastrointestinal safety of the cyclooxygenase-2-selective inhibitor etoricoxib vs. nonselective non-steroidal anti-inflammatory drugs. Methods: Two randomized, double-blind, placebo-and active-controlled studies were performed: (i) daily faecal red blood cell loss was measured in 62 subjects receiving etoricoxib (120 mg once daily), ibuprofen (800 mg t.d.s.) or placebo for 28 days; (ii) the incidence of endoscopically detectable gastric ⁄ duodenal ulcers was determined in 742 osteoarthritis or rheumatoid arthritis

No abstract

No abstract